Roche's Enicepatide Hits Phase II Goals in Diabetes and Obesity Trial
- Enicepatide (CT-388), Roche's dual GLP-1/GIP receptor agonist, met both primary endpoints in a Phase II trial in type 2 diabetes with overweight or obesity.
- At 48 weeks, the top 24 mg dose drove dose-dependent weight loss near 15% with no plateau, plus strong glycemic improvement.
- Most high-dose patients reached near-normal HbA1c, and Roche is now advancing Phase III programs (ENITH-1, ENITH-2) plus a glycemic-control study.
💡 Points
Roche just cashed in its $2.7B Carmot acquisition: a 15% weight-loss curve still climbing at 48 weeks puts enicepatide in contention with Lilly's retatrutide and Novo's CagriSema, not just chasing tirzepatide. More importantly, it hands Roche a credible re-entry into metabolic disease after sitting out the incretin boom — Phase III now becomes the real test of manufacturing and commercial scale-up against entrenched leaders.
Roche's GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes ↗